Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of California, Los Angeles
About this trial
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
Eligibility criteria
Qualifiers
Currently using one or more topical glaucoma antihypertensives
Self-described symptoms of ocular surface discomfort
Xiidra is being prescribed as part of the subject's standard care
Disqualifiers
History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
current use of topical cyclosporine
current use of topical steroids
incisional ocular surgery within 6 months
Trial design
Treatments tested in this trial
- Xiidra (Lifitegrast ophthalmic solution) 5%
Treatment groups
75 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, Los Angeles
Lead sponsor
Bausch & Lomb Incorporated
Collaborator
Source ClinicalTrials.gov